Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch; M. M. G. Leeflang; M. E. Schram; L. E. Campbell; W. H. Irwin McLean; S. Kezic; J. D. Bos; P. I. Spuls; M. A. Middelkamp-Hup

doi:https://doi.org/10.1111/bjd.15191

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch, M. M. G. Leeflang, M. E. Schram, L. E. Campbell, W. H. Irwin McLean, S. Kezic, J. D. Bos, P. I. Spuls, M. A. Middelkamp-Hup

Research output: Contribution to journal › Comment/Letter to the editor › Academic

10 Citations (Scopus)

Abstract

Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved

Original language	English
Pages (from-to)	1745-1746
Journal	British Journal of Dermatology
Volume	177
Issue number	6
Early online date	2016
DOIs	https://doi.org/10.1111/bjd.15191
Publication status	Published - 2017

Access to Document

https://doi.org/10.1111/bjd.15191

Cite this

Roekevisch, E., Leeflang, M. M. G., Schram, M. E., Campbell, L. E., Irwin McLean, W. H., Kezic, S., Bos, J. D., Spuls, P. I., & Middelkamp-Hup, M. A. (2017). Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. British Journal of Dermatology, 177(6), 1745-1746. https://doi.org/10.1111/bjd.15191

@article{19db8d3461274f73b6e19dd5896521dc,

title = "Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment",

abstract = "Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved",

author = "E. Roekevisch and Leeflang, {M. M. G.} and Schram, {M. E.} and Campbell, {L. E.} and {Irwin McLean}, {W. H.} and S. Kezic and Bos, {J. D.} and Spuls, {P. I.} and Middelkamp-Hup, {M. A.}",

year = "2017",

doi = "https://doi.org/10.1111/bjd.15191",

language = "English",

volume = "177",

pages = "1745--1746",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

AU - Roekevisch, E.

AU - Leeflang, M. M. G.

AU - Schram, M. E.

AU - Campbell, L. E.

AU - Irwin McLean, W. H.

AU - Kezic, S.

AU - Bos, J. D.

AU - Spuls, P. I.

AU - Middelkamp-Hup, M. A.

PY - 2017

Y1 - 2017

N2 - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved

AB - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved

U2 - https://doi.org/10.1111/bjd.15191

DO - https://doi.org/10.1111/bjd.15191

M3 - Comment/Letter to the editor

C2 - 27864930

SN - 0007-0963

VL - 177

SP - 1745

EP - 1746

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -